Our preclinical GLAucoma Medication (GLAM) development program sets the ambitious aim to bring a therapeutic solution to preserve vision of patients suffering from glaucoma.

Our first-in-class therapeutic targets a mechanism of action never explored so far by the pharmaceutical industry, while offering the most effective formulation suitable for patients.

On July 2020, the jury of the 22nd i-Lab Innovation Competition of the French Ministry of Research awarded this program the National Prize.

141, rue de la Cardonille
34396 Montpellier Cedex 5
France
[email protected]
© 2019 - MT-act - All Rights Reserved